ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

SGP vs BVS // OPERATING MARGIN

SpyGlass Pharma Inc. (NASDAQ) VS. Bioventus Inc. (Class A) (NASDAQ) • 15-METRIC TALLY: SGP 1 — BVS 4
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SGP VS. BVS) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC SGP BVS SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 68.30% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% 10.40% -45.40 BVS /roic <GO>
EV/EBITDA & P/E Valuation — 26.3x — TIE /valuation <GO>
Free Cash Flow Yield -3.08% 5.77% -8.85 BVS /fcf-yield <GO>
Operating Margin ACTIVE — 9.50% — TIE /operating-margins <GO>
Net Profit Margin — 4.00% — TIE /net-margins <GO>
Revenue Growth (YoY) — -0.90% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 2.25 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 2/9 7/9 -5.00 BVS /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 70.2 45.7 +24.50 SGP /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — 51.2x — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $1.08B $1.12B -$42.2M BVS /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR SGP REV BVS REV SGP GROSS % BVS GROSS % SGP FCF BVS FCF
FY 2025 $116.1M $568.1M — 68.3% -$33.5M $72.1M
FY 2024 $75.8M $573.3M — 67.7% -$24.0M $37.8M
FY 2023 — $512.3M — — — $15.3M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SGP // BETA —
BVS // BETA —